Related Experiment Videos
[Dyslipidemia and subclinical hypothyroidism]
Zorica Caparević1, Gradimir Bojković, Dragos Stojanović
1Klinika za internu medicinu, KBC Dr Dragisa Misović, Dedinje, 11000 Beograd, Heroja Milana Tepića 1.
Medicinski Pregled
|October 21, 2003
Summary
Subclinical hypothyroidism is linked to high cholesterol. Treatment with L-thyroxine significantly reduced cholesterol levels, suggesting early intervention for this common thyroid condition.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Thyroidology
Context:
- Subclinical hypothyroidism (SCH) is characterized by elevated thyroid-stimulating hormone (TSH) with normal free thyroxine (FT4).
- SCH is prevalent and can progress to overt hypothyroidism, often presenting with mild or no symptoms.
- Dyslipidemia is a potential complication of SCH, impacting cardiovascular health.
Purpose:
- To investigate the lipid profiles in patients with subclinical hypothyroidism.
- To evaluate the effects of L-thyroxine therapy on dyslipidemia in SCH.
- To determine if early treatment of SCH with L-thyroxine can mitigate cardiovascular risk factors.
Summary:
- The study examined 35 patients with subclinical hypothyroidism, assessing their dyslipidemia.
- Serum cholesterol, LDL-cholesterol, and apo B levels were elevated in patients with SCH.
- L-thyroxine treatment (50 mcg/d for 3 months) led to significant reductions in these lipid parameters.
Impact:
- Findings indicate a strong association between subclinical hypothyroidism and hypercholesterolemia.
- Thyroid hormone replacement therapy demonstrated beneficial effects on lipid profiles, potentially slowing coronary heart disease progression.
- Early thyroxine treatment is suggested for patients with SCH, especially those with TSH > 10 mU/L, to prevent overt hypothyroidism and manage dyslipidemia.